Parallel scientific advice and special development aspects or product types
Submitted by Anonymous (not verified) on 17 November 2025 - 12:57
Parallel scientific advice and special development aspects or product types
Scientific advice and protocol assistance
Submitted by Anonymous (not verified) on 17 November 2025 - 12:57
Scientific advice and protocol assistance
Scientific advice for public health emergencies and threats
Submitted by Anonymous (not verified) on 17 November 2025 - 12:55
Scientific advice for public health emergencies and threats
Guidance for applicants: the ETF scientific advice that facilitates clinical trial authorisations (SA-CTA)
Submitted by Anonymous (not verified) on 17 November 2025 - 12:52
Guidance for applicants: the ETF scientific advice that facilitates clinical trial authorisations (SA-CTA)
Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 29, Status: Authorised
Submitted by Anonymous (not verified) on 17 November 2025 - 12:50
Human medicines European public assessment report (EPAR): Corlentor, ivabradine, Date of authorisation: 25/10/2005, Revision: 29, Status: Authorised
Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 24, Status: Authorised
Submitted by Anonymous (not verified) on 17 November 2025 - 12:45
Human medicines European public assessment report (EPAR): Procoralan, ivabradine, Date of authorisation: 25/10/2005, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): Imreplys, sargramostim, Date of authorisation: 21/08/2025, Status: Authorised
Submitted by Anonymous (not verified) on 17 November 2025 - 12:05
Human medicines European public assessment report (EPAR): Imreplys, sargramostim, Date of authorisation: 21/08/2025, Status: Authorised
Task Forces
Submitted by Anonymous (not verified) on 17 November 2025 - 10:50
Task Forces
Severe cutaneous adverse reactions - standard template wording for product information
Submitted by Anonymous (not verified) on 17 November 2025 - 9:53
Severe cutaneous adverse reactions - standard template wording for product information
EMEA-002554-PIP02-19
Submitted by Anonymous (not verified) on 14 November 2025 - 15:46
EMEA-002554-PIP02-19